SCHEMBL1998320

SCHEMBL1998320

O=P([O-])([O-])C(N(CCN(C(P(=O)(O)O)P(=O)(O)O)C(P(=O)(O)O)P(=O)(O)O)C(P(=O)(O)O)P(=O)(O)O)P(=O)(O)O.[Na+].[Na+]

nearest known ligand 0.40

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FDPS known ✓ P14324 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1848970 0.92 FDPS (0.48) FDPS
SCHEMBL10475893 0.91 FDPS (0.38) FDPS
SCHEMBL38156 0.85 FDPS (0.50) FDPS
SCHEMBL8063453 0.85 FDPS (0.46) FDPS
Potassium Ion SCHEMBL417831 0.84 FDPS (0.35) FDPS
Potassium Ion SCHEMBL2400306 0.84 FDPS (0.35) FDPS
SCHEMBL1531298 0.83
Water SCHEMBL7073557 0.83 FDPS (0.48) FDPS
Ammonia Solution, Strong SCHEMBL3279112 0.83 FDPS (0.48) FDPS
SCHEMBL8643089 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212038-A1 OIL-IN-WATER PHOTOPROTECTIVE EMULSIONS CONTAINING GEMINI SURFACTANTS AND ASSOCIATIVE POLYMERS L'OREAL (FR) 2011-09-01 US disclosed
US-7959903-B2 Comprises mineral nanopigment based on titanium dioxide; for protecting against ultraviolet radiation L'OREAL (FR) 2011-06-14 US disclosed
US-20050063925-A1 Oil-in-water photoprotective emulsions containing gemini surfactants and associative polymers L'OREAL (FR) 2005-03-24 US disclosed
EP-0467300-B1 Colour reversal material with magnetic tracks in image area FUJI PHOTO FILM CO LTD (JP) 1997-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212038-A1 OIL-IN-WATER PHOTOPROTECTIVE EMULSIONS CONTAINING GEMINI SURFACTANTS AND ASSOCIATIVE POLYMERS APOB, GMNN, DGKI FDPS 2659/4885
US-20050063925-A1 Oil-in-water photoprotective emulsions containing gemini surfactants and associative polymers GMNN, APOB, DGKI FDPS 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.